Table 2.
Current clinical trials employing anthelmintic drugs to treat cancer.
| Drug | Pathology | Official Title of the Study | Phase | Status | Identifier |
|---|---|---|---|---|---|
| Ivermectin | Metastatic TNBC | A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination with Balstilimab in Patients with Metastatic Triple-Negative Breast Cancer with Expansion Cohort in PD-L1 Negative TNBC | I/II | Not yet recruiting | NCT05318469 |
| Niclosamide | FAP | The Chemopreventive Effect of Niclosamide in Patients with Familial Adenomatous Polyposis: Double-Blinded Randomized Controlled Study | II | Last update 5 March 2020 | NCT04296851 |
| Niclosamide | CRC | Phase II Trial to Investigate the Safety and Efficacy of Orally Applied Niclosamide in Patients with Metachronous or Synchronous Metastases of a Colorectal Cancer Progressing After Therapy | II | Last update 12 September 2018 | NCT02519582 |
| Levamisole | Advanced HCC | Multicenter, Randomized, Open, Parallel, Prospective, Exploratory Clinical Study of Arginine Hydrochloride and Levamisole in the Treatment of Advanced HCC | III | Recruiting | NCT03950518 |
| Levamisole | Advanced ICC | The Efficacy of Levamisole Hcl in Advanced Intrahepatic Cholangiocarcinoma. A Multicenter, Open, Randomized, Prospective Study | III | Last update 7 May 2019 |
NCT03940378 |
| Mebendazole | Advanced GI cancer of cancer of unknown origin | A Phase 2a TDM-guided Clinical Study on the Safety and Efficacy of Mebendazole in Patients with Advanced Gastrointestinal Cancer or Cancer of Unknown Origin | II | Terminated (lack of effect) | NCT03628079 |
Abbreviations: TNBC: triple-negative breast cancer; FAP: familial adenomatous polyposis, CRC: colorectal cancer, HCC: hepatocellular carcinoma, ICC: intrahepatic cholangiocarcinoma; GI: gastrointestinal.